1. Studies on the human addiction liability of 2′-hydroxy-5,9-dimethyl-2-(3, 3-dimethylallyl)-6,7-benzomorphan (Win 20,228); a weak narcotic antagonist (II-C-2);FRASER;J. Pharmac. exp. Ther.,1964
2. JASINSKI , D.R. GRIFFITH , J.D. PEVNICK , J.S. CLARK , S.C. 1975 Progress report on studies from the Clinical Pharmacology Section of the Addiction Research Center. Presented at 37th Meeting, Committee on Problems of Drug Dependence, National Research Council, Washington, DC
3. JASINSKI , D.R. GRIFFITH , J.D. PEVNICK , J. GORODETZKY , C. CONE , E. KAY , D. 1977 Progress report from the Clinical Pharmacology Section of the NIDA Addiction Research Center. Presented at 39th Meeting, Committee on Problems of Drug Dependence, National Research Council, Cambridge, Massachusetts
4. Evaluation of nalbuphine for abuse potential;JASINSKI;Clin. pharmac. Ther.,1972